Novocure announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting taking place September 27 - October 1 in San Francisco and simultaneously published in the International Journal of Radiation Oncology Biology and Physics (Red Journal). The pivotal Phase 3 METIS trial enrolled 298 adult patients with 1-10 brain metastases from NSCLC, who were randomized to receive either TTFields therapy and BSC (n=149) or BSC alone (n=149) following SRS of their brain metastases. Baseline patient demographics and characteristics were well balanced across the arms of the study.
The safety profile of TTFields therapy was consistent with that seen in other clinical trials. Grade 1/2 skin issues were the most common device-related adverse events and subcutaneous tissue events. The Phase 3 METIS data, (LBA 03) Tumor Treating Fields ("TTFields") After Stereotactic Radiosurgery (SRS) for Brain Metastases from Non-Small Cell Lung Cancer (NSCLC BM): Final Results of The Phase 3 METIS Trial, will be presented by Dr. Gondi September 29 during the 1:30 - 3:00 PM PT Plenary session in the San Francisco Ballroom at the Moscone Center.
The Phase 3 METIS publication in the International Journal of Radiation oncology Biology and Physics (Red Journal), "Tumor Treating Fields (TTFields) therapy after stereotactic radiosurgery for brain metastases from non -small cell lung cancer: final results of the phase 3 METIS study", will be available online at the company. About Tumor Treating Fields: Tumor Treating Fields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesotheli cancer. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating fields therapy in the treatment of glioblastoma, Non-small cell lung cancer and pancreatic cancer.
Novocure's global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel.
